Cognition Therapeutics rises on FDA support for late-stage trials of Alzheimer’s drug

Shares of drug developer Cognition Therapeutics rise 16.4% to $1.28 in extended trading

Cognition Therapeutics is developing an experimental pill called zervimesine to treat patients with Alzheimer’s disease

CGTX says FDA agreed that Cognition can focus their studies on patients with mild-to-moderate Alzheimer’s who have certain blood test results, making it more likely the medicine will help them

"One of the most important outcomes from the meeting was the FDA’s view that two six-month Phase 3 studies could support a new drug application for zervimesine" Lisa Ricciardi, president and CEO of Cognition Therapeutics says

CGTX stock up 55.6% YTD